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Diagnosis and treatment of cardiac and circulatory dysfunction relies heavily on clinical experience. Model-based approaches can provide a clearer physiological picture. This research tests a subject-specific cardiovascular system (CVS) model-based method on a porcine model of acute pulmonary embolism (APE).
Measurements were recorded in 5 trials. Autologous blood clots were injected into the jugular vein 2-hourly. A minimal set of clinically available or inferable data were used in the identification process (aortic and pulmonary artery pressure, stroke volume, heart rate, global end diastolic volume, and mitral and tricuspid valve closure times). Data was taken at the start and every 30 minutes (4.5hours max) to identify physiological model parameters and their change over time. Model parameters and outputs were compared to experimentally derived metrics and measurements not used in the identification method to validate the model and assess diagnostic capability.
Modelled mean ventricular volumes and maximum ventricular pressures matched measured values with median absolute errors of 4.3% and 4.4%, (less than measurement noise). An increase in pulmonary vascular resistance, the main hemodynamic consequence of APE, was identified in all the pigs and related well to experimental values (R=0.68). Modelled ventricular end diastolic volume ratio increased, signifying the leftward shift of the intra-ventricular septum seen in APE, and compared well to the clinically measured index (R=0.88). Right ventricular contractility decreased in the two pigs that died during the trial.
Subject-specific CVS models can accurately and continuously diagnose and track acute disease dependent cardiovascular changes resulting from APE using readily available measurements.


